XIFIN recently teamed up with William Blair and The Dark Report to conduct a survey to better understand next-generation sequencing trends in the clinical lab space. Here is a general overview of the findings.
Out of 186 responses, the majority of responses were from independent labs (46%) and hospital health systems (40%) with the other 14% being spread out amongst academic centers (7%), tertiary centers (2%) and physician offices (5%).
Beyond the demographic data, William Blair also provided nine major conclusions found after conducting this survey:
- Illumina maintains its leading position based on current installed bases, although newer platforms are starting to crop up
- Overall sentiment around investment in NGS instrumentation and reagents/ consumable over the next 12 months and over the next two to three years continues to be quite bullish.
- NovaSeq was the most popular platform cited for purchase in the near term (within a year) and Thermo Fisher’s [TMO $210.91] Ion S5 was the most cited platform for longer-term purchases.
- Most users that indicated plans to buy instrumentation currently operate NGS.
- Respondent plans after the Medicare NGS NCD were variable.
- Of those that expect to add tests as a result of the NCD, chosen methodology also varies.
- At a high level, reimbursement expectations across all payer categories were slightly more positive than expected.
- Expectations for revenue growth opportunities.
- When asked about potential partnerships, the number of respondents that indicated this was likely was surprising to us, given the Medicare reimbursement environment.
For a full overview of this survey’s results, download the report